Want to see IN:NATCOPHARM full AI Analyst Report?
NATCOPHARM Stock Chart & Stats
₹853.35
₹5.65(0.61%)
At close: 4:00 PM EDT
₹853.35
₹5.65(0.61%)
Day’s Range― - ―
52-Week Range₹785.70 - ₹1,216.20
Previous CloseN/A
Volume230.61K
Average Volume (3M)39.57K
Market Cap
₹146.89B
Enterprise Value₹153.84K
Total Cash (Recent Filing)₹21.29B
Total Debt (Recent Filing)₹0.00
Price to Earnings (P/E)12.9
Beta1.05
Next Earnings
Nov 17, 2026EPS Estimate
10.32Next Dividend Ex-DateN/A
Dividend Yield0.54%
Share Statistics
EPS (TTM)63.89
Shares Outstanding179,109,860
10 Day Avg. Volume36,584
30 Day Avg. Volume39,569
Financial Highlights & Ratios
PEG Ratio-0.51
Price to Book (P/B)1.95
Price to Sales (P/S)4.40
P/FCF Ratio13.03
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)42.93
Revenue Forecast (FY)₹32.51B
Bulls Say, Bears Say
Bulls Say
High Profit MarginsSustained high gross and net margins indicate strong profitability across the company’s pharmaceutical portfolio. This provides room to fund product development, absorb operating pressure, and retain more cash from revenue, supporting durable earnings capacity over the next several quarters.
Low Financial LeverageVery low leverage limits balance-sheet risk and reduces the burden of interest or refinancing obligations. The conservative capital structure gives NATCO Pharma greater flexibility to support operations, invest in growth initiatives, and withstand fluctuations in pharmaceutical revenue.
Improved Cash GenerationImproved operating and free cash flow shows that reported profits are translating into internally generated funds. Strong cash conversion can support research, manufacturing investment, partnerships, and shareholder returns without relying heavily on additional borrowing.
Bears Say
Revenue DeclineThe 2026 revenue contraction highlights inconsistency in the company’s top-line performance despite strong margins. If revenue weakness persists, lower scale and reduced product contribution could limit operating leverage and place pressure on future earnings growth.
Earnings Growth PressureNegative EPS growth indicates that profitability has weakened on a year-over-year basis, even though absolute margins remain robust. Continued earnings pressure could constrain reinvestment capacity and make the company’s financial performance more dependent on new product or market contributions.
Cash Flow VolatilityThe earlier period of low operating cash flow and negative free cash flow shows that cash generation can fluctuate materially across business conditions. Such variability may complicate investment planning and reduce the predictability of funds available for expansion or distributions.
NATCO Pharma Limited News
NATCOPHARM FAQ
What was NATCO Pharma Limited’s price range in the past 12 months?
NATCO Pharma Limited lowest stock price was ₹785.70 and its highest was ₹1216.20 in the past 12 months.
What is NATCO Pharma Limited’s market cap?
NATCO Pharma Limited’s market cap is ₹146.89B.
When is NATCO Pharma Limited’s upcoming earnings report date?
NATCO Pharma Limited’s upcoming earnings report date is Nov 17, 2026 which is in 45 days.
How were NATCO Pharma Limited’s earnings last quarter?
NATCO Pharma Limited released its earnings results on Aug 14, 2026. The company reported ₹11.407 earnings per share for the quarter, beating the consensus estimate of ₹7.978 by ₹3.429.
Is NATCO Pharma Limited overvalued?
According to Wall Street analysts NATCO Pharma Limited’s price is currently Overvalued.
Does NATCO Pharma Limited pay dividends?
NATCO Pharma Limited pays a Semiannually dividend of ₹1.5 which represents an annual dividend yield of 0.54%. See more information on NATCO Pharma Limited dividends here
What is NATCO Pharma Limited’s EPS estimate?
NATCO Pharma Limited’s EPS estimate is 10.32.
How many shares outstanding does NATCO Pharma Limited have?
NATCO Pharma Limited has 179,109,860 shares outstanding.
What happened to NATCO Pharma Limited’s price movement after its last earnings report?
NATCO Pharma Limited reported an EPS of ₹11.407 in its last earnings report, beating expectations of ₹7.978. Following the earnings report the stock price went down -5.235%.
Which hedge fund is a major shareholder of NATCO Pharma Limited?
Currently, no hedge funds are holding shares in IN:NATCOPHARM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
NATCO Pharma Limited
NATCO Pharma Limited, a pharmaceutical company, engages in the research and development, manufacturing, and marketing of finished dosage formulations, active pharmaceutical ingredients (APIs), and intermediates in India, the United States, and internationally. The company offers formulations in various therapeutic areas, including cancers of blood, liver, kidney, lung, brain, breast, and ovary; and APIs in various categories, such as oncology, central nervous system, pain management, and cardiovascular care. It also provides orthopedic products comprising bisphosphonates, which are oral and injectable drugs; and gastroenterology products consisting of novel drugs for chronic hepatitis-B and hepatitis-C, as well as contract manufacturing services. In addition, the company offers neurology, cardiology and diabetology products for the treatment of hypertension, stable angina, and CHF. Further, the company provides agro chemicals and biological pest management solutions for management of insects, diseases, and weeds across a range of crops. NATCO Pharma Limited was incorporated in 1981 and is headquartered in Hyderabad, India.
Technical Analysis
Alembic Pharmaceuticals Limited
―
Granules India Limited
―
―
Strides Pharma Science Ltd
―
Wockhardt Limited
―